These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38751509)

  • 1. Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study.
    Wang T; Zhang P; Di L; Wang X; Yang J; Tong Z; Liu J; Feng J; Liu D; Yu Q; Liu Y; Yu H; Jiang Z
    Transl Breast Cancer Res; 2022; 3():15. PubMed ID: 38751509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience.
    Wu F; Chen M; Wang L; Li N; Wu X; Chen X; Hong Y; Li C; Lin L; Chen K; Huang W; Liu J
    Curr Cancer Drug Targets; 2024; 24(5):490-500. PubMed ID: 37916639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody.
    Liu B; Xie N; Tian C; Feng R; Hu ZY; Li J; Liu L; Xiao H; Yang X; Zeng M; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Tang Y; Wu T; Ouyang Q
    Breast; 2023 Dec; 72():103597. PubMed ID: 37944341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China.
    Liu X; Zhang P; Li C; Song X; Liu Z; Shao W; Li S; Wang X; Yu Z
    Front Oncol; 2023; 13():1136380. PubMed ID: 37404769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial.
    Jin N; Xu Y; Wang S; Sun C; Yan X; Yang F; Liang Y; Chen W; Huang X
    Cancer Pathog Ther; 2024 Jan; 2(1):31-37. PubMed ID: 38328709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.
    Wang H; Nie C; Xu W; Li J; Gou H; Lv H; Chen B; Wang J; Liu Y; He Y; Zhao J; Chen X
    Therap Adv Gastroenterol; 2024; 17():17562848241245455. PubMed ID: 38617123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.
    Gu Q; Zhu M; Wang Y; Gu Y
    Breast Cancer (Dove Med Press); 2024; 16():253-268. PubMed ID: 38812479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of margetuximab plus chemotherapy
    Zhang Q; Ouyang Q; Li W; Chiu J; Yan M; Lu YS; Sun S; Li H; Du Y; Wang X; Sun T; Yin Y; Wang H; Ye F; Shen K; Wang J; Pan Y; Wang S; Yang J; Wu X; Dai MS; Cheng J; Teng Y; Su F; Wu X; He J; Fu P; Yang L; Xin Y; Wang X; Jiang Z
    Transl Breast Cancer Res; 2022; 3():31. PubMed ID: 38751523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1b trial of anti-HER2 antibody inetetamab and pan-HER inhibitor pyrotinib in HER2-positive advanced lung cancer.
    Huang Y; Zhao Y; Huang Y; Yang Y; Zhang Y; Hong S; Zhao H; Zhao S; Zhou T; Chen G; Zhou H; Ma Y; Zhou N; Zhang L; Fang W
    MedComm (2020); 2024 May; 5(5):e536. PubMed ID: 38685972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Phase Ⅲ randomized controlled, multicenter, prospective study of recombinant anti-HER2 humanized monoclonal antibody (Cipterbin) combined with vinorelbine in patients with HER2 positive metastatic breast cancer: the HOPES Study].
    Bian L; Xu BH; Di LJ; Wang T; Wang XJ; Jiao SC; Yang JL; Tong ZS; Liu J; Feng JF; Liu DG; Yu QT; Liu YP; Ma Y; Yu H; Jiang ZF
    Zhonghua Yi Xue Za Zhi; 2020 Aug; 100(30):2351-2357. PubMed ID: 32791810
    [No Abstract]   [Full Text] [Related]  

  • 13. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
    Wang Z; Liu J; Ma F; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Li Q; Xu B
    Breast Cancer Res Treat; 2021 Jul; 188(2):441-447. PubMed ID: 33895900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report.
    Zhou JH; Yi QJ; Li MY; Xu Y; Dong Q; Wang CY; Liu HY
    World J Clin Cases; 2024 Feb; 12(4):820-827. PubMed ID: 38322681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
    Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
    Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
    Tabernero J; Hoff PM; Shen L; Ohtsu A; Shah MA; Cheng K; Song C; Wu H; Eng-Wong J; Kim K; Kang YK
    Lancet Oncol; 2018 Oct; 19(10):1372-1384. PubMed ID: 30217672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab plus pertuzumab in combination with chemotherapy in metastatic HER2-positive breast cancer: a retrospective single-armed cohort study in China.
    Qian Y; Peng Y; Zhou H; Zhang L; Yuan Y
    Ann Transl Med; 2022 Aug; 10(16):877. PubMed ID: 36111041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study.
    Takahashi M; Ohtani S; Nagai SE; Takashima S; Yamaguchi M; Tsuneizumi M; Komoike Y; Osako T; Ito Y; Ikeda M; Ishida K; Nakayama T; Takashima T; Asakawa T; Matsumoto S; Shimizu D; Masuda N
    Breast Cancer Res Treat; 2021 Jan; 185(1):125-134. PubMed ID: 32920732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.